22 May 2013
Keywords: cangene, vzig, trial, canadian, company, expects, begin
Article | 27 November 1995
- Canadian company Cangene expects to begin a trial shortly for its
second hyperimmune product VZIG, an immunoglobulin that is highly
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 August 1995
21 May 2013
© 2013 thepharmaletter.com